Positive UK reimbursement decision for Alimera's Iluvien

20 June 2019

Georgia, USA-based ophthalmic specialist Alimera (Nasdaq: ALIM) has won a positive reimbursement decision in the UK, for its therapy Iluvien (fluocinolone acetonide).

The National Institute for Health and Care Excellence (NICE) recommended the product as an option for preventing relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

The NICE’s decision means that Iluvien will now be routinely available for use in the UK’s national healthcare provider, the National Health Service.

NIU-PS is a difficult to treat inflammatory condition which can be sight threatening. The unpredictability of uveitis recurrence can make it difficult for people to live normal lives.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK